- R&D expenses: $31.0M, +51% YoY
- Net loss: $35.4M vs $24.6M YoY
- Strong cash position: $903M vs $362M YoY
CEO Brian Lian: "2024 was an exciting and extremely productive year for Viking. During the year, the company reported positive data from four different clinical trials, including results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, the Phase 1 study of an oral tablet formulation of VK2735 for obesity, the Phase 2b VOYAGE study of VK2809 for MASH and fibrosis, and the Phase 1b study of VK0214 for X-ALD."
🌱Revenue & Growth
- No revenue reported in Q4 2024 and Q4 2023
- R&D expenses: $31.0M vs $20.5M in Q4 2023
- G&A expenses: $15.3M vs $8.8M in Q4 2023
💰Profits & Financials
- Q4 Net loss: $35.4M ($0.32/share) vs $24.6M ($0.25/share) YoY
- FY2024 Net loss: $110.0M ($1.01/share) vs $85.9M ($0.91/share) YoY
- Cash and investments: $903M as of Dec 31, 2024
- Interest income: $10.8M vs $4.7M in Q4 2023
📌Business Highlights
- Completed Phase 2 VENTURE study of VK2735 for obesity with up to 14.7% weight loss
- Initiated Phase 2a VENTURE-Oral Dosing trial for oral VK2735
- Reported positive Phase 1b results for VK0214 in X-ALD treatment
🔮Future Outlook
- Phase 3 studies for subcutaneous VK2735 planned for Q2 2025
- Phase 2 VENTURE-Oral data expected in 2H 2025
- Plans to file IND for DACRA program in 2025
- Upcoming investor conferences in February-April 2025